

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN.

**ILUVIEN® (fluocinolone acetonide intravitreal implant)**

**0.19 mg**

**For Intravitreal Injection**

**Initial U.S. Approval: 1963**

### INDICATIONS AND USAGE

ILUVIEN contains a corticosteroid and is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. (1)

### DOSAGE AND ADMINISTRATION

- For ophthalmic intravitreal injection. (2.1)
- The intravitreal injection procedure should be carried out under aseptic conditions. (2.2)
- Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. (2.2)

### DOSAGE FORMS AND STRENGTHS

Non-bioerodable intravitreal implant containing 0.19 mg fluocinolone acetonide in a drug delivery system. (3)

### CONTRAINDICATIONS

- Ocular or periocular infections (4.1)
- Glaucoma (4.2)
- Hypersensitivity (4.3)

### WARNINGS AND PRECAUTIONS

- Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1)
- Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. (5.2)
- The implant may migrate into the anterior chamber if the posterior lens capsule is not intact. (5.3)

### ADVERSE REACTIONS

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Alimera Sciences, Inc. at 1-844-445-8843 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**See 17 for PATIENT COUNSELING INFORMATION**

**Revised: 9/2014**

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 General Dosing Information

#### 2.2 Administration

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

#### 4.1 Ocular or Periocular Infections

#### 4.2 Glaucoma

#### 4.3 Hypersensitivity

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Intravitreal Injection-related Effects

#### 5.2 Steroid-related Effects

#### 5.3 Risk of Implant Migration

### 6 ADVERSE REACTIONS

#### 6.1 Clinical Studies Experience

#### 6.2 Postmarketing Experience

### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

#### 8.3 Nursing Mothers

#### 8.4 Pediatric Use

#### 8.5 Geriatric Use

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

#### 12.3 Pharmacokinetics

### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

**ILUVIEN®** (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 General Dosing Information

For ophthalmic intravitreal injection.

#### 2.2 Administration

The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.

The injection procedure for **ILUVIEN** is as follows:

1. The exterior of the tray should **not** be considered sterile. An assistant (non-sterile) should remove the tray from the carton and examine the tray and lid for damage. If damaged, do not use unit.

If acceptable, the assistant should peel the lid from the tray **without touching the interior surface**.

2. Visually check through the viewing window of the preloaded applicator to ensure that there is a drug implant inside.
3. Remove the applicator from the tray with sterile gloved hands **touching only the sterile interior tray surface and applicator**.

The protective cap on the needle should not be removed until the patient is ready to be injected.

Prior to injection, the applicator tip must be kept above the horizontal plane to ensure that the implant is properly positioned within the applicator.

4. To reduce the amount of air administered with the implant, the administration procedure requires two steps. Before inserting the needle into the eye, push the applicator button down and slide it to the first stop (at the curved black marks alongside the button track). At the first stop, release the button and it should move to the UP position. If the button does not rise to the UP position, do not proceed with this unit.
5. Optimal placement of the implant is inferior to the optic disc and posterior to the equator of the eye. Measure 4 millimeters inferotemporal from the limbus with the aid of calipers for point of entry into the sclera.
6. Carefully remove the protective cap from the needle and inspect the tip to ensure it is not bent.
7. Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes. Insert the needle through the conjunctiva and sclera. To release the implant, while the button is in the UP position, advance the button by sliding it forward to the end of the button track and remove the needle. Note: Ensure that the button reaches the end of the track before removing the needle.
8. Remove the lid speculum and perform indirect ophthalmoscopy to verify placement of the implant, adequate central retinal artery perfusion and absence of any other complications.

Following the injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.

### 3 DOSAGE FORMS AND STRENGTHS

**ILUVIEN** is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 µg/day and lasting 36 months.

## 4 CONTRAINDICATIONS

### 4.1 Ocular or Periocular Infections

**ILUVIEN** is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

### 4.2 Glaucoma

**ILUVIEN** is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.

### 4.3 Hypersensitivity

**ILUVIEN** is contraindicated in patients with known hypersensitivity to any components of this product.

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Intravitreal Injection-related Effects

Intravitreal injections, including those with **ILUVIEN**, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection [*see Patient Counseling Information (17)*].

### 5.2 Steroid-related Effects

Use of corticosteroids including **ILUVIEN** may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.

Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

### 5.3 Risk of Implant Migration

Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

## 6 ADVERSE REACTIONS

### 6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions associated with ophthalmic steroids including **ILUVIEN** include cataract formation and subsequent cataract surgery, elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

**ILUVIEN** was studied in two multicenter, randomized, sham-controlled, masked trials in which patients with diabetic macular edema were treated with either **ILUVIEN** (n=375) or sham (n=185).

Table 1 summarizes safety data available when the last subject completed the last 36 month follow up visit for the two primary **ILUVIEN** trials. In these trials, subjects were eligible for retreatment no earlier than 12 months after study entry. Over the three year follow up period, approximately 75% of the **ILUVIEN** treated subjects received only one **ILUVIEN** implant.

The most common ocular (study eye) and non-ocular adverse reactions are shown in Tables 1 and 2:

**Table 1: Ocular Adverse Reactions Reported by  $\geq 1\%$  of Patients and  
Non-ocular Adverse Reactions Reported by  $\geq 5\%$  of Patients**

| Adverse Reactions               | ILUVIEN<br>(N=375)<br>n (%) | Sham<br>(N=185)<br>n (%)  |
|---------------------------------|-----------------------------|---------------------------|
| <b>Ocular</b>                   |                             |                           |
| Cataract <sup>1</sup>           | 192/235 <sup>2</sup> (82%)  | 61/121 <sup>2</sup> (50%) |
| Myodesopsia                     | 80 (21%)                    | 17 (9%)                   |
| Eye pain                        | 57 (15%)                    | 25 (14%)                  |
| Conjunctival haemorrhage        | 50 (13%)                    | 21 (11%)                  |
| Posterior capsule opacification | 35 (9%)                     | 6 (3%)                    |
| Eye irritation                  | 30 (8%)                     | 11 (6%)                   |
| Vitreous detachment             | 26 (7%)                     | 12 (7%)                   |
| Conjunctivitis                  | 14 (4%)                     | 5 (3%)                    |
| Corneal oedema                  | 13 (4%)                     | 3 (2%)                    |
| Foreign body sensation in eyes  | 12 (3%)                     | 4 (2%)                    |
| Eye pruritus                    | 10 (3%)                     | 3 (2%)                    |
| Ocular hyperaemia               | 10 (3%)                     | 3 (2%)                    |
| Optic atrophy                   | 9 (2%)                      | 2 (1%)                    |
| Ocular discomfort               | 8 (2%)                      | 1 (1%)                    |
| Photophobia                     | 7 (2%)                      | 2 (1%)                    |
| Retinal exudates                | 7 (2%)                      | 0 (0%)                    |
| Anterior chamber cell           | 6 (2%)                      | 1 (1%)                    |
| Eye discharge                   | 6 (2%)                      | 1 (1%)                    |
| <b>Non-ocular</b>               |                             |                           |
| Anemia                          | 40 (11%)                    | 10 (5%)                   |
| Headache                        | 33 (9%)                     | 11 (6%)                   |
| Renal Failure                   | 32 (9%)                     | 10 (5%)                   |
| Pneumonia                       | 28 (7%)                     | 8 (4%)                    |

<sup>1</sup> Includes cataract, cataract nuclear, cataract subcapsular, cataract cortical and cataract diabetic in patients who were phakic at baseline. Among these patients, 80% of **ILUVIEN** subjects vs. 27% of sham-controlled subjects underwent cataract surgery.


<sup>2</sup> 235 of the 375 **ILUVIEN** subjects were phakic at baseline; 121 of 185 sham-controlled subjects were phakic at baseline.

### Increased intraocular Pressure

**Table 2: Summary of Elevated IOP Related Adverse Reactions**

| Event                                                       | ILUVIEN<br>(N=375)<br>n (%) | Sham<br>(N=185)<br>n (%) |
|-------------------------------------------------------------|-----------------------------|--------------------------|
| IOP elevation $\geq 10$ mmHg from Baseline                  | 127 (34%)                   | 18 (10%)                 |
| IOP elevation $\geq 30$ mmHg                                | 75 (20%)                    | 8 (4%)                   |
| Any IOP-lowering medication                                 | 144 (38%)                   | 26 (14%)                 |
| Any surgical intervention for elevated intraocular pressure | 18 (5%)                     | 1 (1%)                   |

Figure 1: Mean IOP during the study



### Cataracts and Cataract Surgery

At baseline, 235 of the 375 **ILUVIEN** subjects were phakic; 121 of 185 sham-controlled subjects were phakic. The incidence of cataract development in patients who had a phakic study eye was higher in the **ILUVIEN** group (82%) compared with Sham (50%). The median time of cataract being reported as an adverse event was approximately 12 months in the **ILUVIEN** group and 9 months in the Sham group. Among these patients, 80% of **ILUVIEN** subjects vs. 27% of sham-controlled subjects underwent cataract surgery, generally within the first 18 months (Median Month 15 for both **ILUVIEN** group and for Sham) of the studies.

## 6.2 Postmarketing Experience

The following reactions have been identified during post-marketing use of **ILUVIEN** in clinical practice. Because they are reported voluntarily estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to **ILUVIEN**, or a combination of these factors, include reports of drug administration error and reports of the drug being ineffective.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

Pregnancy Category C

There are no adequate and well-controlled studies of **ILUVIEN** in pregnant women. Animal reproduction studies have not been conducted with fluocinolone acetonide. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. **ILUVIEN** should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### 8.3 Nursing Mothers

Systemically administered corticosteroids are present in human milk and could suppress growth and interfere with endogenous corticosteroid production. The systemic concentration of fluocinolone acetonide following intravitreal treatment with **ILUVIEN** is low [see Clinical Pharmacology (12.3)]. It is not known whether intravitreal treatment with **ILUVIEN** could result in sufficient

systemic absorption to produce detectable quantities in human milk. Exercise caution when **ILUVIEN** is administered to a nursing woman.

#### 8.4 Pediatric Use

Safety and effectiveness of **ILUVIEN** in pediatric patients have not been established.


#### 8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

### 11 DESCRIPTION

**ILUVIEN** is a sterile non-bioerodable intravitreal implant containing 0.19 mg (190 mcg) fluocinolone acetonide in a 36-month sustained-release drug delivery system. **ILUVIEN** is designed to release fluocinolone acetonide at an initial rate of 0.25 µg/day. **ILUVIEN** is preloaded into a single-use applicator to facilitate injection of the implant directly into the vitreous. The drug substance is a synthetic corticosteroid, fluocinolone acetonide.

The chemical name for fluocinolone acetonide is (6 $\alpha$ ,11 $\beta$ , 16 $\alpha$ )-6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione. Its chemical structure is:



MW 452.50; molecular formula C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>O<sub>6</sub>

Fluocinolone acetonide is a white or almost white, microcrystalline powder, practically insoluble in water, soluble in methanol, ethanol, chloroform and acetone, and sparingly soluble in ether.

Each **ILUVIEN** consists of a light brown 3.5mm x 0.37mm implant containing 0.19 mg of the active ingredient fluocinolone acetonide and the following inactive ingredients: polyimide tube, polyvinyl alcohol, silicone adhesive and water for injection.

### 12 CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

Corticosteroids inhibit inflammatory responses to a variety of inciting agents. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

Corticosteroids are thought to act by inhibition of phospholipase A<sub>2</sub> via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>.

#### 12.3 Pharmacokinetics

In a human pharmacokinetic study of **ILUVIEN**, fluocinolone acetonide concentrations in plasma were below the lower limit of quantitation of the assay (100 pg/mL) at all post-administration time points from Day 7 through Month 36 following intravitreal administration of a 0.2 mcg/day or 0.5 mcg/day fluocinolone acetonide insert.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been conducted to determine the carcinogenic potential or the effect on fertility of **ILUVIEN**.

Fluocinolone acetonide was not genotoxic *in vitro* in the Ames test (*S. typhimurium* and *E. coli*) and the mouse lymphoma TK assay, or *in vivo* in the mouse bone marrow micronucleus assay.

## 14 CLINICAL STUDIES

The efficacy of **ILUVIEN** was assessed in two three year, randomized (2:1, active: sham), multicenter, double-masked, parallel-groups studies that enrolled patients with diabetic macular edema that had previously been treated with laser photocoagulation.

The primary efficacy endpoint in both trials was the proportion of subjects in whom vision had improved by 15 letters or more from baseline after 24 months of follow-up.

**Table 3: Baseline BCVA (Letters)**

|                       | Study 1                    |                        | Study 2                    |                        |
|-----------------------|----------------------------|------------------------|----------------------------|------------------------|
|                       | <b>ILUVIEN<br/>(N=190)</b> | <b>Sham<br/>(N=95)</b> | <b>ILUVIEN<br/>(N=186)</b> | <b>Sham<br/>(N=90)</b> |
| <b>Mean (SD)</b>      | 53 (13)                    | 55 (11)                | 53 (12)                    | 55 (11)                |
| <b>Median (Range)</b> | 57 (19-75)                 | 58 (25-69)             | 56 (20-70)                 | 58 (21-68)             |

**Table 4: Visual Acuity outcomes at Month 24 (All randomized subjects with LOCF)**


| Study          | Outcomes                                  | ILUVIEN    | Sham       | Estimated Difference (95% CI) |
|----------------|-------------------------------------------|------------|------------|-------------------------------|
| 1 <sup>a</sup> | Gain of $\geq 15$ letters in BCVA (n (%)) | 51 (27%)   | 14 (15%)   | 12.1% (2.6%, 21.6%)           |
|                | Loss of $\geq 15$ letters in BCVA (n (%)) | 26 (14%)   | 5 (5%)     | 8.4% (1.8%, 15.1%)            |
|                | Mean change from baseline in BCVA (SD)    | 3.7 (18.7) | 3.2 (13.1) | 1.8 (-2.8, 6.3)               |
| 2 <sup>b</sup> | Gain of $\geq 15$ letters in BCVA (n (%)) | 57 (31%)   | 16 (18%)   | 13.0% (2.7%, 23.4%)           |
|                | Loss of $\geq 15$ letters in BCVA (n (%)) | 22 (12%)   | 9 (10%)    | 1.8% (-5.9%, 9.6%)            |
|                | Mean change from baseline in BCVA (SD)    | 5.2 (18.0) | 0.0 (15.6) | 6.1 (1.4, 10.8)               |

<sup>a</sup>Study 1: **ILUVIEN**, N=190; Sham, N=95

<sup>b</sup>Study 2: **ILUVIEN**, N=186; Sham, N=90


Visual acuity outcomes by lens status (Phakic or Pseudophakic) at different visits are presented in Figure 2 and Figure 3. The occurrence of cataracts impacted visual acuity during the study. Patients who were pseudophakic at baseline achieved greater mean BCVA change from baseline at the Month 24 study visit.

**Figure 2: Proportion of subjects with  $\geq 15$  Letters Improvement from Baseline BCVA in the Study Eye**





**Figure 3: Mean BCVA Change from Baseline**



The BCVA outcomes for the Pseudophakic and Phakic subgroups from Studies 1 and 2 at Month 24 are presented in Table 4.

**Table 5: Visual Acuity outcomes at Month 24 (Subgroup for pooled data with LOCF)**

| Lens Status               | Outcomes                                  | ILUVIEN    | Sham       | Estimated Difference (95% CI) |
|---------------------------|-------------------------------------------|------------|------------|-------------------------------|
| <sup>a</sup> Pseudophakic | Gain of $\geq 15$ letters in BCVA (n (%)) | 39 (28%)   | 8 (13%)    | 15.4% (4.4%, 26.3%)           |
|                           | Loss of $\geq 15$ letters in BCVA (n (%)) | 7 (5%)     | 7 (11%)    | -5.9% (-14.4%, 2.5%)          |
|                           | Mean change from baseline in BCVA (SD)    | 7.1 (14.5) | 1.5 (17.4) | 5.6 (0.7, 10.6)               |
| <sup>b</sup> Phakic       | Gain of $\geq 15$ letters in BCVA (n (%)) | 69 (29%)   | 22 (18%)   | 11.1% (2.1%, 20.1%)           |
|                           | Loss of $\geq 15$ letters in BCVA (n (%)) | 41 (17%)   | 7 (6%)     | 11.6% (5.2%, 18%)             |
|                           | Mean change from baseline in BCVA (SD)    | 2.8 (20.1) | 1.8 (12.6) | 1 (-2.5, 4.4)                 |

<sup>a</sup>Pseudophakic : ILUVIEN, N=140; Sham, N=64

<sup>b</sup>Phakic: ILUVIEN, N=236; Sham, N=121

## 16 HOW SUPPLIED/STORAGE AND HANDLING

**ILUVIEN®** (fluocinolone acetonide intravitreal implant) 0.19 mg is supplied in a sterile single use preloaded applicator with a 25-gauge needle, packaged in a tray sealed with a lid inside a carton.

NDC 68611-190-02

**Storage:** Store at 15° - 30° C (59° - 86° F).

## 17 PATIENT COUNSELING INFORMATION

### **Steroid-related Effects**

Advise patients that a cataract may occur after treatment with **ILUVIEN**. If this occurs, advise patients that their vision will decrease, and they will need an operation to remove the cataract and restore their vision.

Advise patients that they may develop increased intraocular pressure with **ILUVIEN** treatment, and the increased IOP may need to be managed with eye drops, or surgery.

### **Intravitreal Injection-related Effects**

Advise patients that in the days following intravitreal injection of **ILUVIEN**, patients are at risk for potential complications including in particular, but not limited to, the development of endophthalmitis or elevated intraocular pressure.

### **When to Seek Physician Advice**

Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.

### **Driving and Using Machines**

Inform patients that they may experience temporary visual blurring after receiving an intravitreal injection. Advise patients not to drive or use machines until this has been resolved.

Manufactured for:  
Alimera Sciences, Inc.  
6120 Windward Parkway  
Alpharetta, GA 30005

Patented. See: [www.alimerasciences.com](http://www.alimerasciences.com)

**ALIMERA**  
SCIENCES